Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Deferred Revenue (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Current Deferred Revenue data on record, last reported at $21.2 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 86.03% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $21.2 million, up 86.03%, while the annual FY2025 figure was $21.2 million, 86.03% up from the prior year.
  • Current Deferred Revenue reached $21.2 million in Q4 2025 per TGTX's latest filing, down from $26.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $26.4 million in Q3 2025 and bottomed at $152000.0 in Q4 2023.
  • Average Current Deferred Revenue over 5 years is $6.4 million, with a median of $700000.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 69.6% in 2023, then soared 7409.21% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $600000.0 in 2021, then dropped by 16.67% to $500000.0 in 2022, then plummeted by 69.6% to $152000.0 in 2023, then skyrocketed by 7409.21% to $11.4 million in 2024, then surged by 86.03% to $21.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $21.2 million in Q4 2025, $26.4 million in Q3 2025, and $23.9 million in Q2 2025.